Nipocalimab

Phase 3

Johnson & Johnson (JNJ)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

JNJPhase 3$649.6B

Nipocalimab Phase 3 Est. Readout

Nipocalimab• Arthritis, Rheumatoid115

Q3 2027~QConfirmedSTALE

CT.gov

00%

Q2 '27

JNJPhase 3$649.6B

Nipocalimab Phase 3 Est. Readout

Nipocalimab• Arthritis, Rheumatoid201

Q2 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Arthritis, Rheumatoid

LLYLY2189102

Phase 2

View Full Landscape

Drug Information

Target Indication

Arthritis, Rheumatoid

Clinical Trial

NCT06028438

Last updated: 5/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/28/2025

Imaavy

Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain